Global Blood Theraps Drug Patent Portfolio
Global Blood Theraps owns 1 orange book drug protected by 11 US patents Given below is the list of Global Blood Theraps's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10493035 | Tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde | 12 Oct, 2037 | Active |
| US11020382 | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde | 02 Dec, 2036 | Active |
| US11944612 | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde | 02 Dec, 2036 | Active |
| US10722502 | Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde | 06 Feb, 2035 | Active |
| US11452720 | Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde | 06 Feb, 2035 | Active |
| US9447071 | Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde | 06 Feb, 2035 | Active |
| US9248199 | 1:1 adducts of sickle hemoglobin | 29 Jan, 2034 | Active |
| US9018210 | Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation | 25 Nov, 2033 | Active |
| US10017491 | Compounds and uses thereof for the modulation of hemoglobin | 28 Dec, 2032 | Active |
| US10034879 | Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation | 28 Dec, 2032 | Active |
| US10806733 | Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation | 28 Dec, 2032 | Active |
Latest Legal Activities on Global Blood Theraps's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Global Blood Theraps.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Patent eGrant Notification | 02 Apr, 2024 | US11944612 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 02 Apr, 2024 | US11944612 |
|
Recordation of Patent Grant Mailed
Critical
| 02 Apr, 2024 | US11944612 |
| Mail Patent eGrant Notification | 02 Apr, 2024 | US11944612 |
|
Email Notification
Critical
| 02 Apr, 2024 | US11944612 |
| Recordation of Patent eGrant | 02 Apr, 2024 | US11944612 |
|
Email Notification
Critical
| 14 Mar, 2024 | US11944612 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 14 Mar, 2024 | US10806733 |
|
Issue Notification Mailed
Critical
| 13 Mar, 2024 | US11944612 |
|
Application Is Considered Ready for Issue
Critical
| 27 Feb, 2024 | US11944612 |
| Dispatch to FDC | 27 Feb, 2024 | US11944612 |
|
Issue Fee Payment Received
Critical
| 23 Feb, 2024 | US11944612 |
|
Issue Fee Payment Verified
Critical
| 23 Feb, 2024 | US11944612 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 08 Feb, 2024 | US9447071 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 14 Dec, 2023 | US10722502 |
Global Blood Theraps Drug Patents' Oppositions Filed in EPO
Global Blood Theraps drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Oct 13, 2021, by Bülle Dr., Jan. This opposition was filed on patent number EP15746995A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP15746995A | Oct, 2021 | Bülle Dr., Jan | Granted and Under Opposition |
Global Blood Theraps's Family Patents
Global Blood Theraps drugs have patent protection in a total of 38 countries. It's US patent count contributes only to 23.6% of its total global patent coverage. 2 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Global Blood Theraps Drug List
Given below is the complete list of Global Blood Theraps's drugs and the patents protecting them.
1. Oxbryta
Oxbryta is protected by 11 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10493035 | Tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
12 Oct, 2037
(12 years from now)
| Active |
| US11020382 | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
02 Dec, 2036
(11 years from now)
| Active |
| US11944612 | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
02 Dec, 2036
(11 years from now)
| Active |
| US10722502 | Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
06 Feb, 2035
(10 years from now)
| Active |
| US11452720 | Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
06 Feb, 2035
(10 years from now)
| Active |
| US9447071 | Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
06 Feb, 2035
(10 years from now)
| Active |
| US9248199 | 1:1 adducts of sickle hemoglobin |
29 Jan, 2034
(9 years from now)
| Active |
| US9018210 | Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation |
25 Nov, 2033
(8 years from now)
| Active |
| US10017491 | Compounds and uses thereof for the modulation of hemoglobin |
28 Dec, 2032
(8 years from now)
| Active |
| US10034879 | Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation |
28 Dec, 2032
(8 years from now)
| Active |
| US10806733 | Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation |
28 Dec, 2032
(8 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Oxbryta's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List